Dialog Box

23 June 2020

EHA 2020 Congress - Indolent lymphoma updates

Indolent lymphoma updates
European Hematology Association (EHA) congress

Professor John Seymour, Consultant Haematologist. Director of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital

Professor John Seymour discussed with Deborah Sims some of the key and emerging treatments that are being currently investigated or available for patients with chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma and other indolent lymphomas. He provided an excellent overview of how these treatments work, side effects and new treatments.



The key abstracts that were discussed from the conference include:

Fixed duration venetoclax, obintuzumab for previously untreated chronic lymphocytic leukaemia: follow up of efficacy and safety results from the multicentre, open label, randomised phase 3 CLL14 trial

CLL2-Give, a prospective, open-label, multicentre phase II trial of obinutuzumab (GA101, G), ibrutinib, plus venetoclax in untreated patients with CLL with 17p deletion/TP53 mutation.

First line ibrutinib and venetoclax for patients with chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL): efficacy and safety results from CAPTIVATE MR cohort.

Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL): ASCEND final results. (Prof Paolo Ghia – oral presentation)

Matching adjusted indirect comparisons of efficacy and safety of acalabrutinib versus ibrutinib in treatment-naïve chronic lymphocytic leukaemia. (Prof Matt Davids -eposter)

Initial results of a multicentre, investigator-initiated study of MRD driven time limited therapy with zanubrutinib, obintuzumab and venetoclax (Dr Andrew Zleenetz – oral presentation)

Interim analysis of ZUMA-5: a phase 2 study of axicabtagene clioleucel (Axi-cek) in patients with relapsed/refractory indolent non-Hodgkin lymphoma (Dr Caron Jacobson – oral presentation)

Ibrutinib, venetoclax plus obintuzumab in newly diagnosed mantle cell lymphoma. (Prof Steven Le Gouill – oral presentation)

ASPEN: results of a phase 3 randomised trial of zanubrutinib versus ibrutinib for patients with Waldenstrom’s macroglobulinemia (WM). (Meletios Dimopouls & Constantine Tam (ASCO20) – oral presentation)

For questions or comments, please contact Donna Gairns, National Nurse Director on 1800 953 081 or email nurse@lymphoma.org.au

Category: Research
Tags: indolent CLL lymphoma treatment lymphoma updates expert EHA,